A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610

Hiroshi Urakawa, Junki Mizusawa, Kazuhiro Tanaka, Junko Eba, Hiroaki Hiraga, Akira Kawai, Yoshihiro Nishida, Masami Hosaka, Yukihide Iwamoto, Haruhiko Fukuda, Toshihumi Ozaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A randomized phase III trial was planned to commence in October 2017. Resectable giant cell tumor of bone (GCTB) without possible postoperative large bone defect has been treated by curettage with local adjuvant treatment, with the local recurrence rate found to be as high as 24.6-30.8%. The aim of this study is to confirm the superiority of preoperative denosumab for patients with GCTB without possible postoperative large bone defect. A total of 106 patients will be accrued from 34 Japanese institutions over 5 years. The primary endpoint is relapse-free survival (RFS). Secondary endpoints include overall survival, joint-preserved survival, local RFS, metastasis-free survival, adverse events, serious adverse events, surgical and postoperative complications, and discontinuation of denosumab. This trial is conducted by the Bone and Soft Tissue Tumor Study Group in the Japan Clinical Oncology Group and has been registered in the UMIN Clinical Trials Registry as UMIN000029451 [http://www.umin.ac.jp/ctr/index.htm].

Original languageEnglish
Pages (from-to)379-382
Number of pages4
JournalJapanese journal of clinical oncology
Volume49
Issue number4
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Giant Cell Tumor of Bone
Medical Oncology
Curettage
Japan
Survival
Bone and Bones
Recurrence
Disease-Free Survival
Registries
Joints
Clinical Trials
Neoplasm Metastasis
Denosumab
Neoplasms

Keywords

  • curettage
  • giant cell tumor of bone
  • Japan
  • phase iii
  • preoperative denosumab

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A randomized phase III trial of denosumab before curettage for giant cell tumor of bone : Japan Clinical Oncology Group Study JCOG1610. / Urakawa, Hiroshi; Mizusawa, Junki; Tanaka, Kazuhiro; Eba, Junko; Hiraga, Hiroaki; Kawai, Akira; Nishida, Yoshihiro; Hosaka, Masami; Iwamoto, Yukihide; Fukuda, Haruhiko; Ozaki, Toshihumi.

In: Japanese journal of clinical oncology, Vol. 49, No. 4, 01.04.2019, p. 379-382.

Research output: Contribution to journalArticle

Urakawa, H, Mizusawa, J, Tanaka, K, Eba, J, Hiraga, H, Kawai, A, Nishida, Y, Hosaka, M, Iwamoto, Y, Fukuda, H & Ozaki, T 2019, 'A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610', Japanese journal of clinical oncology, vol. 49, no. 4, pp. 379-382. https://doi.org/10.1093/jjco/hyz004
Urakawa, Hiroshi ; Mizusawa, Junki ; Tanaka, Kazuhiro ; Eba, Junko ; Hiraga, Hiroaki ; Kawai, Akira ; Nishida, Yoshihiro ; Hosaka, Masami ; Iwamoto, Yukihide ; Fukuda, Haruhiko ; Ozaki, Toshihumi. / A randomized phase III trial of denosumab before curettage for giant cell tumor of bone : Japan Clinical Oncology Group Study JCOG1610. In: Japanese journal of clinical oncology. 2019 ; Vol. 49, No. 4. pp. 379-382.
@article{515a71bfb7fc4943912edb96258c8703,
title = "A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610",
abstract = "A randomized phase III trial was planned to commence in October 2017. Resectable giant cell tumor of bone (GCTB) without possible postoperative large bone defect has been treated by curettage with local adjuvant treatment, with the local recurrence rate found to be as high as 24.6-30.8{\%}. The aim of this study is to confirm the superiority of preoperative denosumab for patients with GCTB without possible postoperative large bone defect. A total of 106 patients will be accrued from 34 Japanese institutions over 5 years. The primary endpoint is relapse-free survival (RFS). Secondary endpoints include overall survival, joint-preserved survival, local RFS, metastasis-free survival, adverse events, serious adverse events, surgical and postoperative complications, and discontinuation of denosumab. This trial is conducted by the Bone and Soft Tissue Tumor Study Group in the Japan Clinical Oncology Group and has been registered in the UMIN Clinical Trials Registry as UMIN000029451 [http://www.umin.ac.jp/ctr/index.htm].",
keywords = "curettage, giant cell tumor of bone, Japan, phase iii, preoperative denosumab",
author = "Hiroshi Urakawa and Junki Mizusawa and Kazuhiro Tanaka and Junko Eba and Hiroaki Hiraga and Akira Kawai and Yoshihiro Nishida and Masami Hosaka and Yukihide Iwamoto and Haruhiko Fukuda and Toshihumi Ozaki",
year = "2019",
month = "4",
day = "1",
doi = "10.1093/jjco/hyz004",
language = "English",
volume = "49",
pages = "379--382",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - A randomized phase III trial of denosumab before curettage for giant cell tumor of bone

T2 - Japan Clinical Oncology Group Study JCOG1610

AU - Urakawa, Hiroshi

AU - Mizusawa, Junki

AU - Tanaka, Kazuhiro

AU - Eba, Junko

AU - Hiraga, Hiroaki

AU - Kawai, Akira

AU - Nishida, Yoshihiro

AU - Hosaka, Masami

AU - Iwamoto, Yukihide

AU - Fukuda, Haruhiko

AU - Ozaki, Toshihumi

PY - 2019/4/1

Y1 - 2019/4/1

N2 - A randomized phase III trial was planned to commence in October 2017. Resectable giant cell tumor of bone (GCTB) without possible postoperative large bone defect has been treated by curettage with local adjuvant treatment, with the local recurrence rate found to be as high as 24.6-30.8%. The aim of this study is to confirm the superiority of preoperative denosumab for patients with GCTB without possible postoperative large bone defect. A total of 106 patients will be accrued from 34 Japanese institutions over 5 years. The primary endpoint is relapse-free survival (RFS). Secondary endpoints include overall survival, joint-preserved survival, local RFS, metastasis-free survival, adverse events, serious adverse events, surgical and postoperative complications, and discontinuation of denosumab. This trial is conducted by the Bone and Soft Tissue Tumor Study Group in the Japan Clinical Oncology Group and has been registered in the UMIN Clinical Trials Registry as UMIN000029451 [http://www.umin.ac.jp/ctr/index.htm].

AB - A randomized phase III trial was planned to commence in October 2017. Resectable giant cell tumor of bone (GCTB) without possible postoperative large bone defect has been treated by curettage with local adjuvant treatment, with the local recurrence rate found to be as high as 24.6-30.8%. The aim of this study is to confirm the superiority of preoperative denosumab for patients with GCTB without possible postoperative large bone defect. A total of 106 patients will be accrued from 34 Japanese institutions over 5 years. The primary endpoint is relapse-free survival (RFS). Secondary endpoints include overall survival, joint-preserved survival, local RFS, metastasis-free survival, adverse events, serious adverse events, surgical and postoperative complications, and discontinuation of denosumab. This trial is conducted by the Bone and Soft Tissue Tumor Study Group in the Japan Clinical Oncology Group and has been registered in the UMIN Clinical Trials Registry as UMIN000029451 [http://www.umin.ac.jp/ctr/index.htm].

KW - curettage

KW - giant cell tumor of bone

KW - Japan

KW - phase iii

KW - preoperative denosumab

UR - http://www.scopus.com/inward/record.url?scp=85064493148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064493148&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyz004

DO - 10.1093/jjco/hyz004

M3 - Article

C2 - 30796832

AN - SCOPUS:85064493148

VL - 49

SP - 379

EP - 382

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 4

ER -